
Mariana Lazo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3917696/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Accessibility and availability of alcohol outlets around schools: An ecological study in the city of Madrid, Spain, according to socioeconomic area-level. Environmental Research, 2022, 204, 112323.	3.7	14
2	Associations between aflatoxin B 1 â€albumin adduct levels with metabolic conditions in Guatemala: A crossâ€sectional study. Health Science Reports, 2022, 5, e495.	0.6	2
3	Alcohol outlets and alcohol consumption in changing environments: prevalence and changes over time. Substance Abuse Treatment, Prevention, and Policy, 2022, 17, 7.	1.0	4
4	Vaccination against <scp>COVID</scp> â€19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis. Liver International, 2022, 42, 942-944.	1.9	5
5	Validation of the accuracy of the FASTâ,,¢ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS ONE, 2022, 17, e0266859.	1.1	20
6	The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. The Lancet Gastroenterology and Hepatology, 2022, 7, 552-559.	3.7	25
7	Circulating bile acid concentrations and nonâ€alcoholic fatty liver disease in Guatemala. Alimentary Pharmacology and Therapeutics, 2022, 56, 321-329.	1.9	12
8	Obesity, Galectinâ€3, and Incident Heart Failure: The ARIC Study. Journal of the American Heart Association, 2022, 11, e023238.	1.6	8
9	COVID-19 Outcomes Among the Hispanic Population of 27 Large US Cities, 2020–2021. American Journal of Public Health, 2022, 112, 1034-1044.	1.5	8
10	Letter: is it appropriate to use a fatty liver index >60 as an alternative criterion for nonâ€elcoholic fatty liver disease? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 378-379.	1.9	0
11	Letter: association of circulating bile acid concentrations and nonâ€alcoholic fatty liver disease—authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 374-375.	1.9	2
12	Editorial: higher levels of certain serum bile acids in nonâ€elcoholic fatty liver disease–new insights from Guatemala.Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 361-362.	1.9	0
13	Association of blood manganese, selenium with steatosis, fibrosis in the National Health and Nutrition Examination Survey, 2017-18. Environmental Research, 2022, 213, 113647.	3.7	9
14	Racial/Ethnic Disparities in Hepatocellular Carcinoma: The Role of Neighborhood Socioeconomic Deprivation. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1254-1256.	1.1	2
15	Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population. Clinical Gastroenterology and Hepatology, 2021, 19, 2606-2614.e4.	2.4	7
16	Alcohol type and ideal cardiovascular health among adults of the Multi-Ethnic Study of Atherosclerosis. Drug and Alcohol Dependence, 2021, 218, 108358.	1.6	8
17	The association of sex steroid hormone concentrations with nonâ€alcoholic fatty liver disease and liver enzymes in US men. Liver International, 2021, 41, 300-310.	1.9	30
18	Understanding Immigration as a Social Determinant of Health: Cardiovascular Disease in Hispanics/Latinos and South Asians in the United States. Current Atherosclerosis Reports, 2021, 23, 25.	2.0	21

#	Article	IF	CITATIONS
19	High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care, 2021, 44, 1657-1663.	4.3	22
20	Sixâ€year changes in Nâ€ŧerminal proâ€brain natriuretic peptide and changes in weight and risk of obesity. Obesity, 2021, 29, 1215-1222.	1.5	1
21	Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study. Digestive and Liver Disease, 2021, 53, 873-878.	0.4	2
22	Impact of Public Health Policies on Alcoholâ€Associated Liver Disease in Latin America: An Ecological Multinational Study. Hepatology, 2021, 74, 2478-2490.	3.6	27
23	P-30 IMPACT OF PUBLIC HEALTH POLICIES ON ALCOHOL-ASSOCIATED LIVER DISEASE IN LATIN AMERICA: AN ECOLOGICAL MULTI-NATIONAL STUDY. Annals of Hepatology, 2021, 24, 100394.	0.6	Ο
24	Utility of non-HDL-C and apoB targets in the context of new more aggressive lipid guidelines. American Journal of Preventive Cardiology, 2021, 7, 100203.	1.3	2
25	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 2021, 385, 1559-1569.	13.9	406
26	Alcohol Consumption and Incident Kidney Disease: Results From the Atherosclerosis Risk in Communities Study. , 2020, 30, 22-30.		30
27	Recruitment of trial participants through electronic medical record patient portal messaging: A pilot study. Clinical Trials, 2020, 17, 30-38.	0.7	22
28	Associations between <i>Helicobacter pylori</i> with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. Helicobacter, 2020, 25, e12756.	1.6	16
29	Aflatoxin B ₁ exposure and liver cirrhosis in Guatemala: a case–control study. BMJ Open Gastroenterology, 2020, 7, e000380.	1.1	14
30	Nonalcoholic fatty liver disease and type 2 diabetes: a burgeoning problem with unclear solutions. Hepatobiliary Surgery and Nutrition, 2020, 9, 514-517.	0.7	2
31	Validation of the accuracy of the fast score for detecting non-alcoholic steatohepatitis patients at high risk of becoming cirrhotic in a North American cohort. Journal of Hepatology, 2020, 73, S426.	1.8	0
32	Physical Activity and Incident Heart Failure in Highâ€Risk Subgroups: The ARIC Study. Journal of the American Heart Association, 2020, 9, e014885.	1.6	11
33	Alcohol Consumption and Risk of Hospitalizations and Mortality in the Atherosclerosis Risk in Communities Study. Alcoholism: Clinical and Experimental Research, 2020, 44, 1646-1657.	1.4	6
34	Multicenter Validation of Association Between Decline in MRIâ€₽DFF and Histologic Response in NASH. Hepatology, 2020, 72, 1219-1229.	3.6	79
35	The Moderate Alcohol and Cardiovascular Health Trial (MACH15): Design and methods for a randomized trial of moderate alcohol consumption and cardiometabolic risk. European Journal of Preventive Cardiology, 2020, 27, 1967-1982.	0.8	15
36	Liver Enzymes and Risk of Stroke: The Atherosclerosis Risk in CommunitiesÂ(ARIC) Study. Journal of Stroke, 2020, 22, 357-368.	1.4	20

Mariana Lazo

#	Article	IF	CITATIONS
37	Economic Insecurity and Deaths of Despair in US Counties. American Journal of Epidemiology, 2019, 188, 2131-2139.	1.6	46
38	Association between aflatoxin-albumin adduct levels and tortilla consumption in Guatemalan adults. Toxicology Reports, 2019, 6, 465-471.	1.6	19
39	Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001–2010. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1331-1338.	1.1	10
40	Response of 1,5â€anhydroglucitol level to intensive glucose―and bloodâ€pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial. Diabetes, Obesity and Metabolism, 2019, 21, 2017-2023.	2.2	9
41	Validation of the Use of Electronic Medical Records for Identification of Post-gastric Bypass Hypoglycemia Cases. Obesity Surgery, 2019, 29, 2126-2131.	1.1	2
42	Alcohol consumption and incident diabetes: The Atherosclerosis Risk in Communities (ARIC) study. Diabetologia, 2019, 62, 770-778.	2.9	22
43	A Pilot Genomeâ€Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. Hepatology Communications, 2019, 3, 1571-1584.	2.0	16
44	Coffee consumption and liver-related hospitalizations and deaths in the ARIC study. European Journal of Clinical Nutrition, 2019, 73, 1133-1140.	1.3	5
45	Associations of Insulin Resistance and Glycemia With Liver Enzymes in Hispanic/Latino Youths. Journal of Clinical Gastroenterology, 2019, 53, e46-e53.	1.1	9
46	Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599â€^912 current drinkers in 83 prospective studies. Lancet, The, 2018, 391, 1513-1523.	6.3	858
47	Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure. Circulation, 2018, 137, 2142-2151.	1.6	46
48	The Association of Arsenic Exposure and Arsenic Metabolism With the Metabolic Syndrome and Its Individual Components: Prospective Evidence From the Strong Heart Family Study. American Journal of Epidemiology, 2018, 187, 1598-1612.	1.6	68
49	Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Scientific Reports, 2018, 8, 4718.	1.6	68
50	Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy. Circulation, 2018, 137, 10-19.	1.6	92
51	Weight History and Subclinical Myocardial Damage. Clinical Chemistry, 2018, 64, 201-209.	1.5	16
52	lslet autoantibody positivity in overweight and obese adults with type 2 diabetes. Autoimmunity, 2018, 51, 408-416.	1.2	18
53	Effects of visceral adipose tissue reduction on CVD risk factors independent of weight loss: The Look AHEAD study. Endocrine Research, 2017, 42, 86-95.	0.6	3
54	Expression of MYD88 in Adipose Tissue of Obese People: Is There Some Role in the Development of Metabolic Syndrome?. Metabolic Syndrome and Related Disorders, 2017, 15, 80-85.	0.5	5

#	Article	IF	CITATIONS
55	Physical Activity, Obesity, and SubclinicalÂMyocardial Damage. JACC: Heart Failure, 2017, 5, 377-384.	1.9	20
56	Confluence of Epidemics of Hepatitis C, Diabetes, Obesity, and Chronic Kidney Disease in the United States Population. Clinical Gastroenterology and Hepatology, 2017, 15, 1957-1964.e7.	2.4	30
57	COMPARISON OF THE NOVEL METHOD VERSUS THE FRIEDEWALD EQUATION IN ESTIMATING LOW-DENSITY LIPOPROTEIN-CHOLESTEROL BASED ON FASTING STATUS. Journal of the American College of Cardiology, 2017, 69, 1697.	1.2	4
58	Association between family history of diabetes and cardiovascular disease and lifestyle risk factors in the United States population: The 2009–2012 National Health and Nutrition Examination Survey. Preventive Medicine, 2017, 96, 129-134.	1.6	18
59	High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study. Diabetes Care, 2017, 40, 261-269.	4.3	25
60	Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut, 2017, 66, 323-329.	6.1	125
61	Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. Journal of Hepatology, 2017, 67, 1274-1280.	1.8	120
62	Binge drinking and well-being in European older adults: do gender and region matter?. European Journal of Public Health, 2017, 27, 692-699.	0.1	8
63	Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence. PLoS ONE, 2017, 12, e0189255.	1.1	47
64	Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV. AIDS Patient Care and STDs, 2016, 30, 200-207.	1.1	28
65	Moderate Alcohol Consumption and Chronic Disease: The Case for a Longâ€Term Trial. Alcoholism: Clinical and Experimental Research, 2016, 40, 2283-2291.	1.4	36
66	Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study. Clinical Chemistry, 2016, 62, 1202-1210.	1.5	16
67	Obesity and Subtypes of Incident Cardiovascular Disease. Journal of the American Heart Association, 2016, 5, .	1.6	149
68	Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology, 2016, 86, 1136-1142.	1.5	130
69	Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clinical Biochemistry, 2016, 49, 657-662.	0.8	28
70	N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity. Circulation, 2016, 133, 631-638.	1.6	96
71	Effectiveness of an Activity Tracker- and Internet-Based Adaptive Walking Program for Adults: A Randomized Controlled Trial. Journal of Medical Internet Research, 2016, 18, e34.	2.1	92
72	Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. American Heart Journal, 2015, 170, 961-967.	1.2	38

#	Article	IF	CITATIONS
73	Prevalence and characteristics of individuals without diabetes and hypertension who underwent bariatric surgery: lessons learned about metabolically healthy obese. Surgery for Obesity and Related Diseases, 2015, 11, 142-146.	1.0	13
74	Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrology Dialysis Transplantation, 2015, 30, 77-83.	0.4	32
75	Association Between Endogenous Sex Hormones and Liver Fat in a Multiethnic Study of Atherosclerosis. Clinical Gastroenterology and Hepatology, 2015, 13, 1686-1693.e2.	2.4	72
76	Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study. International Journal of Cardiology, 2015, 187, 651-657.	0.8	36
77	N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Hypertension, 2015, 28, 1262-1266.	1.0	30
78	Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin. Current Diabetes Reports, 2015, 15, 116.	1.7	30
79	Prevalence of self-reported sleep duration and sleep habits in type 2 diabetes patients in South Trinidad. Journal of Epidemiology and Global Health, 2015, 5, S35.	1.1	36
80	The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. Journal of Hepatology, 2015, 62, 841-847.	1.8	37
81	Association between serum uric acid and nonalcoholic fatty liver disease in the US population. Journal of the Formosan Medical Association, 2015, 114, 314-320.	0.8	54
82	Abstract 19523: Liver Injury in Alcohol Drinkers and Incidence of Heart Failure - The Atherosclerosis Risk in Communities Study. Circulation, 2015, 132, .	1.6	0
83	Sex Differences in Diabetes and Risk of Incident Coronary Artery Disease in Healthy Young and Middle-Aged Adults. Diabetes Care, 2014, 37, 830-838.	4.3	101
84	Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clinical Biochemistry, 2014, 47, 132-134.	0.8	17
85	Obesity, Subclinical Myocardial Injury, and Incident Heart Failure. JACC: Heart Failure, 2014, 2, 600-607.	1.9	81
86	Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage. Circulation, 2014, 130, 1374-1382.	1.6	174
87	Elevated hepatic enzymes and incidence of venous thromboembolism: a prospective study. Annals of Epidemiology, 2014, 24, 817-821.e2.	0.9	14
88	High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III. American Journal of Clinical Nutrition, 2014, 99, 320-327.	2.2	205
89	Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III. Journal of Gastroenterology, 2013, 48, 1151-1159.	2.3	31
90	Association Between Variants in or Near PNPLA3, GCKR, and PPP1R3B With Ultrasound-Defined Steatosis Based on Data From the Third National Health and Nutrition Examination Survey. Clinical Gastroenterology and Hepatology, 2013, 11, 1183-1190.e2.	2.4	128

#	Article	IF	CITATIONS
91	Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988–1994. American Journal of Epidemiology, 2013, 178, 38-45.	1.6	693
92	Elevated ALT and GGT predict all-cause mortality and hepatocellular carcinoma in Taiwanese male: a case-cohort study. Hepatology International, 2013, 7, 1040-1049.	1.9	29
93	Effect of Positive Well-Being on Incidence of Symptomatic Coronary Artery Disease. American Journal of Cardiology, 2013, 112, 1120-1125.	0.7	19
94	NH 2 -Terminal Pro–Brain Natriuretic Peptide and Risk of Diabetes. Diabetes, 2013, 62, 3189-3193.	0.3	86
95	Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology, 2012, 56, 952-960.	3.6	150
96	Nonalcoholic fatty liver disease across ethnoâ€racial groups: Do Asianâ€American adults represent a new atâ€risk population?. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 501-509.	1.4	25
97	Effect of Problem-Solving-Based Diabetes Self-Management Training on Diabetes Control in a Low Income Patient Sample. Journal of General Internal Medicine, 2011, 26, 972-978.	1.3	96
98	Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology, 2011, 54, 1082-1090.	3.6	1,128
99	Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ: British Medical Journal, 2011, 343, d6891-d6891.	2.4	314
100	Low Glycated Hemoglobin and Liver Disease in the U.S. Population. Diabetes Care, 2011, 34, 2548-2550.	4.3	27
101	Hepatocellular Carcinoma: Response to TACE Assessed with Semiautomated Volumetric and Functional Analysis of Diffusion-weighted and Contrast-enhanced MR Imaging Data. Radiology, 2011, 260, 752-761.	3.6	99
102	Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes. Diabetes Care, 2010, 33, 2156-2163.	4.3	313
103	Availability of healthy foods and dietary patterns: the Multi-Ethnic Study of Atherosclerosis. American Journal of Clinical Nutrition, 2009, 89, 897-904.	2.2	209
104	Development and Pilot Evaluation of Literacy-Adapted Diabetes and CVD Education in Urban, Diabetic African Americans. Journal of General Internal Medicine, 2008, 23, 1491-1494.	1.3	24
105	Examining a Bidirectional Association Between Depressive Symptoms and Diabetes. JAMA - Journal of the American Medical Association, 2008, 299, 2751.	3.8	724
106	The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective. Seminars in Liver Disease, 2008, 28, 339-350.	1.8	624
107	Usability of a diabetes and cardiovascular disease education module in an African American, diabetic sample with physical, visual, and cognitive impairment Rehabilitation Psychology, 2008, 53, 1-8.	0.7	18
108	Brief Communication: Clinical Implications of Short-Term Variability in Liver Function Test Results. Annals of Internal Medicine, 2008, 148, 348.	2.0	121

#	Article	IF	CITATIONS
109	Drawing Conclusions about Short-Term Variability in Liver Function Test Results. Annals of Internal Medicine, 2008, 149, 145.	2.0	0
110	Impact of Energy Intake, Physical Activity, and Population-wide Weight Loss on Cardiovascular Disease and Diabetes Mortality in Cuba, 1980 2005. American Journal of Epidemiology, 2007, 166, 1374-1380.	1.6	130
111	Patterns and Predictors of Changes in Adherence to Highly Active Antiretroviral Therapy: Longitudinal Study of Men and Women. Clinical Infectious Diseases, 2007, 45, 1377-1385.	2.9	123
112	Better health statistics: the Cuban experience. Lancet, The, 2006, 367, 985-986.	6.3	3
113	Cardiovascular diseases mortality in Cuba, Mexico, Puerto Rico and US Hispanic populations. Prevention and Control: the Official Journal of the World Heart Federation, 2006, 2, 63-71.	0.3	11
114	Omega-3 Fatty Acid Prevents Heart Rate Variability Reductions Associated with Particulate Matter. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1534-1540.	2.5	118
115	Cardiac Autonomic Changes Associated With Fish Oil vs Soy Oil Supplementation in the Elderly <xref rid="AFF1">[*]. Chest, 2005, 127, 1102.</xref 	0.4	75